![Jinzi Wu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jinzi Wu
Directeur Général chez ASCLETIS PHARMA INC.
Fortune : 58 M $ au 30/06/2024
Profil
Jinzi J.
Wu is the founder of Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
(founded in 2011) and Gannex Pharma Co Ltd.
(founded in 2019).
Dr. Wu is also the founder of Ascletis Pharma, Inc. Dr. Wu's current job positions include Chief Executive Officer & Director at Ascletis BioScience Co., Ltd.
(since 2013), Chief Executive Officer & Director at Ascletis Xinnuo Medicine Co., Ltd (since 2018), Director at Ascletis Pharma China Co., Ltd.
(since 2018), Director at Soundridge Pharmaceuticals (Hong Kong) Co., Ltd.
(since 2019), Member at The BayHelix Group, and Manager at Gannex LLC (since 2020).
Dr. Wu's former job positions include Director at Sagimet Biosciences, Inc. (2019-2024), Principal at Immunex Corp.
(1992-2002), Principal at Novartis AG (1992-2002), Vice President at GSK Plc, Principal at Sanofi India Ltd.
(1992-2002), Senior Scientist at Novartis Pharmaceuticals Corp.
(1997-2000), Vice President-Preclinical & Basic Research at Ambrilia Biopharma, Inc. (2004-2008), Vice President-Research & Development at PhageTech, Inc. (2002-2004), and Vice President at Ascletis Pharmaceuticals Co., Ltd.
(2014-2021).
Dr. Wu's education includes a doctorate degree from the University of Arizona (conferred in 1996) and undergraduate and graduate degrees from Nanjing University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
ASCLETIS PHARMA, INC.
50,79% | 05/03/2024 | 514 393 664 ( 50,79% ) | 53 M $ | 30/06/2024 |
18/07/2023 | 1 654 701 ( 5,44% ) | 6 M $ | 30/06/2024 |
Postes actifs de Jinzi Wu
Sociétés | Poste | Début |
---|---|---|
ASCLETIS PHARMA INC. | Directeur Général | - |
Ascletis Pharma China Co., Ltd. | Directeur/Membre du Conseil | 01/03/2018 |
Gannex LLC | Corporate Officer/Principal | 01/10/2020 |
Gannex Pharma Co Ltd. | Directeur Général | 01/01/2019 |
Soundridge Pharmaceuticals (Hong Kong) Co., Ltd. | Directeur/Membre du Conseil | 01/04/2019 |
Ascletis Xinnuo Medicine Co., Ltd | Directeur Général | 01/07/2018 |
Ascletis BioScience Co., Ltd. | Directeur Général | 01/04/2013 |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
![]() Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Directeur Général | - |
The BayHelix Group | Corporate Officer/Principal | 08/04/2011 |
Anciens postes connus de Jinzi Wu
Sociétés | Poste | Fin |
---|---|---|
░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Jinzi Wu
Nanjing University | Graduate Degree |
University of Arizona | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 5 |
---|---|
GSK PLC | Health Technology |
NOVARTIS AG | Health Technology |
SANOFI INDIA LIMITED | Health Technology |
ASCLETIS PHARMA INC. | Health Technology |
SAGIMET BIOSCIENCES INC. | Health Technology |
Entreprise privées | 13 |
---|---|
Ambrilia Biopharma, Inc.
![]() Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
Ascletis BioScience Co., Ltd. | |
Immunex Corp.
![]() Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
The BayHelix Group | |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
![]() Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
Ascletis Xinnuo Medicine Co., Ltd | |
Ascletis Pharma China Co., Ltd. | |
Soundridge Pharmaceuticals (Hong Kong) Co., Ltd. | |
Gannex Pharma Co Ltd. | |
Gannex LLC | |
PhageTech, Inc.
![]() PhageTech, Inc. Miscellaneous Commercial ServicesCommercial Services PhageTech, Inc. provides medical services. The firm develops bacteriophage sensors related tests for detecting analytes in urine, blood, and other body fluids. Its technology is used for advanced diagnostics, such as early stage cancer detection, drug dosage monitoring, and time sensitive diseases and conditions. The company was founded by Richard W. Henson, Gregory Weiss, and Reginald Penner in 2014 and is headquartered in Irvine, CA. | Commercial Services |
Novartis Pharmaceuticals Corp.
![]() Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Ascletis Pharmaceuticals Co., Ltd. |